Safe and Effective Chin Augmentation With the Hyaluronic Acid Injectable Filler, VYC-20L

Kenneth Beer, Joely Kaufman-Janette, David Bank, Brian Biesman, Steven Dayan, William Kim, Smita Chawla, Andrew Schumacher, Kenneth Beer, Joely Kaufman-Janette, David Bank, Brian Biesman, Steven Dayan, William Kim, Smita Chawla, Andrew Schumacher

Abstract

Background: VYC-20L is a hyaluronic acid soft tissue filler with lidocaine designed to restore facial volume.

Objective: Evaluate the safety and effectiveness of VYC-20L in patients with chin retrusion.

Materials and methods: Adults with chin retrusion were randomized (3:1) to receive VYC-20L in the chin at study onset (treatment group) or 6 months later (control group). The primary effectiveness end point was ≥1-point improvement on the Allergan Chin Retrusion Scale (ACRS) from baseline at Month 6. Safety assessments included injection site responses (ISRs) and adverse events (AEs).

Results: VYC-20L was administered to 192 participants (treatment group, n = 144; control group, n = 48). At Month 6, significantly more participants had an ACRS response in the treatment versus control group (56.3% vs 27.5%; p = .0019). Effectiveness was also demonstrated by the proportion of participants with improved/much improved Global Aesthetic Improvement Scale scores and responses on the FACE-Q Satisfaction with Chin questionnaire and FACE-Q Psychological Wellbeing module. Treatment benefit remained evident at Month 12. Most common ISRs were tenderness (81.1%) and firmness (75.1%). One participant (0.5%) discontinued the study due to 2 treatment-related serious AEs of facial cellulitis and injection site inflammation, both resolved without sequelae.

Conclusion: VYC-20L significantly improved an ACRS response and was generally safe and well tolerated.

Trial registration: ClinicalTrials.gov NCT02833077.

Conflict of interest statement

This study was sponsored by Allergan plc, Dublin, Ireland. Medical writing assistance was provided to the authors by W. Kim of Allergan plc, Irvine, CA. All authors met the ICMJE authorship criteria. Neither honoraria nor any other form of compensation was provided for authorship. K. Beer, J. Kaufman-Janette, D. Bank, and S. Dayan have received funding as an investigator, consultant, and trainer for Allergan. B. Biesman has received consulting fees and research funding from Allergan. W. Kim, S. Chawla, and A. Schumacher are employees of Allergan plc and may own stock in the company.

Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Society for Dermatologic Surgery, Inc.

References

    1. Jones D, Flynn TC. Hyaluronic acids: clinical applications. In: Jonas D, editor. Injectable Fillers: Principles and Practice. Oxford, United Kingdom: Blackwell Publishing Ltd.; 2010; pp. 158–74.
    1. American Society of Plastic Surgeons. 2008 Minimally-Invasive Cosmetic Procedures. Available from: . Accessed January 30, 2020.
    1. American Society of Plastic Surgeons. 2018 Cosmetic Surgical Procedures. 2018. Available from: . Accessed January 30, 2020.
    1. Alam M, Tung R. Injection technique in neurotoxins and fillers: indications, products, and outcomes. J Am Acad Dermatol 2018;79:423–35.
    1. Jones D, Murphy DK. Volumizing hyaluronic acid filler for midface volume deficit: 2-year results from a pivotal single-blind randomized controlled study. Dermatol Surg 2013;39:1602–12.
    1. Lee EI. Aesthetic alteration of the chin. Semin Plast Surg 2013;27:155–60.
    1. de Maio M, Wu WTL, Goodman GJ, Monheit G; Alliance for the Future of Aesthetics Consensus C. Facial assessment and injection guide for botulinum toxin and injectable hyaluronic acid fillers: focus on the lower face. Plast Reconstr Surg 2017;140:393e–404e.
    1. Naini FB, Donaldson AN, McDonald F, Cobourne MT. Assessing the influence of chin prominence on perceived attractiveness in the orthognathic patient, clinician and layperson. Int J Oral Maxillofac Surg 2012;41:839–46.
    1. Sykes JM. Rejuvenation of the aging neck. Facial Plast Surg 2001;17:99–107.
    1. Kridel RWH, Patel S. Cheek and chin implants to enhance facelift results. Facial Plast Surg 2017;33:279–84.
    1. Fedok FG, Mittelman H. Augmenting the prejowl: deciding between fat, fillers, and implants. Facial Plast Surg 2016;32:513–9.
    1. Callan P, Goodman GJ, Carlisle I, Liew S, et al. Efficacy and safety of a hyaluronic acid filler in subjects treated for correction of midface volume deficiency: a 24 month study. Clin Cosmet Investig Dermatol 2013;6:81–9.
    1. Raspaldo H. Volumizing effect of a new hyaluronic acid sub-dermal facial filler: a retrospective analysis based on 102 cases. J Cosmet Laser Ther 2008;10:134–42.
    1. Hoffmann K; Juvederm Voluma Study Investigators G. Volumizing effects of a smooth, highly cohesive, viscous 20-mg/mL hyaluronic acid volumizing filler: prospective European study. BMC Dermatol 2009;9:9.
    1. Carruthers J, Carruthers A, Tezel A, Kraemer J, et al. Volumizing with a 20-mg/mL smooth, highly cohesive, viscous hyaluronic acid filler and its role in facial rejuvenation therapy. Dermatol Surg 2010;36(Suppl 3):1886–92.
    1. Fischer TC. A European evaluation of cosmetic treatment of facial volume loss with Juvederm Voluma in patients previously treated with Restylane Sub-Q. J Cosmet Dermatol 2010;9:291–6.
    1. Hexsel D, Soirefmann M, Porto MD, Siega C, et al. Double-blind, randomized, controlled clinical trial to compare safety and efficacy of a metallic cannula with that of a standard needle for soft tissue augmentation of the nasolabial folds. Dermatol Surg 2012;38:207–14.
    1. Sivek R, Emer J. Use of a blunt-tipped microcannula for soft tissue filler injection in the treatment of linear scleroderma (en coup de sabre). Dermatol Surg 2014;40:1439–41.
    1. Sahan A, Karaosmanoglu N, Ozdemir Cetinkaya P. Chin augmentation with the use of cannula from a single, midline entry point: evaluation of 50 patients. J Cosmet Dermatol 2020;19:1301–6.
    1. Sadeghpour M, Quatrano NA, Bonati LM, Arndt KA, et al. Delayed-onset nodules to differentially crosslinked hyaluronic acids: comparative incidence and risk assessment. Dermatol Surg 2019;45:1085–94.
    1. Funt D, Pavicic T. Dermal fillers in aesthetics: an overview of adverse events and treatment approaches. Clin Cosmet Investig Dermatol 2013;6:295–316.
    1. Belmontesi M, Grover R, Verpaele A. Transdermal injection of Restylane SubQ for aesthetic contouring of the cheeks, chin, and mandible. Aesthet Surg J 2006;26:S28–34.
    1. Jansen DA, Graivier MH. Evaluation of a calcium hydroxylapatite-based implant (Radiesse) for facial soft-tissue augmentation. Plast Reconstr Surg 2006;118(3 Suppl):22S–30S, discussion 1S-3S.
    1. Fulton J, Caperton C. The optimal filler: immediate and long-term results with emulsified silicone (1,000 centistokes) with cross-linked hyaluronic acid. J Drugs Dermatol 2012;11:1336–41.
    1. Ogilvie P, Sattler G, Gaymans F, Belhaouari L, et al. Safe, effective chin and jaw restoration with VYC-25L hyaluronic acid injectable gel. Dermatol Surg 2019;45:1294–303.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel